InterCure Ltd. (NASDAQ: INCR) Stock Competitors & Peer Comparison
See INCR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for INCR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INCR | $5.51 | -4.34% | 65.3M | -12.72 | -$0.43 | N/A |
| TAK | $18.23 | +1.11% | 57.2B | 12.93 | $1.39 | +3.46% |
| HLN | $10.07 | +0.40% | 44.4B | 18.80 | $0.54 | +1.23% |
| TEVA | $36.19 | -0.69% | 42B | 12.30 | $2.93 | N/A |
| ZTS | $77.25 | +0.19% | 32.4B | 11.74 | $6.58 | +2.71% |
| VTRS | $16.63 | +0.73% | 19.4B | 6.60 | $2.52 | +2.89% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.91 | -0.04% | 11.9B | 22.56 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.17 | +0.33% | 10.1B | 19.93 | $0.61 | +0.68% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
INCR vs TAK Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, TAK has a market cap of 57.2B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while TAK trades at $18.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas TAK's P/E ratio is 12.93. In terms of profitability, INCR's ROE is -0.09%, compared to TAK's ROE of +0.02%. Regarding short-term risk, INCR is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for INCR.Check TAK's competition here
Haleon plc (NYSE: HLN)
INCR vs HLN Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, HLN has a market cap of 44.4B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while HLN trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas HLN's P/E ratio is 18.80. In terms of profitability, INCR's ROE is -0.09%, compared to HLN's ROE of +0.17%. Regarding short-term risk, INCR is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for INCR.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
INCR vs TEVA Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, TEVA has a market cap of 42B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while TEVA trades at $36.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas TEVA's P/E ratio is 12.30. In terms of profitability, INCR's ROE is -0.09%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, INCR is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for INCR.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
INCR vs ZTS Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ZTS has a market cap of 32.4B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ZTS trades at $77.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ZTS's P/E ratio is 11.74. In terms of profitability, INCR's ROE is -0.09%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, INCR is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
INCR vs VTRS Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, VTRS has a market cap of 19.4B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while VTRS trades at $16.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas VTRS's P/E ratio is 6.60. In terms of profitability, INCR's ROE is -0.09%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, INCR is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for INCR.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
INCR vs ITCI Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ITCI's P/E ratio is -180.64. In terms of profitability, INCR's ROE is -0.09%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, INCR is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
INCR vs ELAN Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ELAN has a market cap of 11.9B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ELAN trades at $23.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ELAN's P/E ratio is 22.56. In terms of profitability, INCR's ROE is -0.09%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, INCR is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
INCR vs CTLT Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas CTLT's P/E ratio is -27.84. In terms of profitability, INCR's ROE is -0.09%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, INCR is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for INCR.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
INCR vs RDY Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while RDY trades at $12.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas RDY's P/E ratio is 19.93. In terms of profitability, INCR's ROE is -0.09%, compared to RDY's ROE of +0.09%. Regarding short-term risk, INCR is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for INCR.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
INCR vs ALKS Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ALKS trades at $47.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ALKS's P/E ratio is 49.68. In terms of profitability, INCR's ROE is -0.09%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, INCR is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
INCR vs LNTH Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while LNTH trades at $100.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas LNTH's P/E ratio is 16.95. In terms of profitability, INCR's ROE is -0.09%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, INCR is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for INCR.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
INCR vs AMRX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while AMRX trades at $17.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas AMRX's P/E ratio is 19.64. In terms of profitability, INCR's ROE is -0.09%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, INCR is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for INCR.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
INCR vs INDV Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while INDV trades at $34.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas INDV's P/E ratio is 9.47. In terms of profitability, INCR's ROE is -0.09%, compared to INDV's ROE of -2.16%. Regarding short-term risk, INCR is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for INCR.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
INCR vs ALVOW Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, INCR's ROE is -0.09%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, INCR is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for INCR.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
INCR vs RGC Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while RGC trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas RGC's P/E ratio is -387.32. In terms of profitability, INCR's ROE is -0.09%, compared to RGC's ROE of -2.32%. Regarding short-term risk, INCR is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for INCR.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
INCR vs SUPN Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while SUPN trades at $43.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas SUPN's P/E ratio is 14.29. In terms of profitability, INCR's ROE is -0.09%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, INCR is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for INCR.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
INCR vs BHC Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while BHC trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas BHC's P/E ratio is 1.65. In terms of profitability, INCR's ROE is -0.09%, compared to BHC's ROE of +0.89%. Regarding short-term risk, INCR is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for INCR.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
INCR vs DCPH Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas DCPH's P/E ratio is -11.58. In terms of profitability, INCR's ROE is -0.09%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, INCR is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for INCR.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
INCR vs AVDL Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, INCR's ROE is -0.09%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, INCR is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for INCR.Check AVDL's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
INCR vs HCM Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while HCM trades at $11.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas HCM's P/E ratio is 4.46. In terms of profitability, INCR's ROE is -0.09%, compared to HCM's ROE of +0.01%. Regarding short-term risk, INCR is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for INCR.Check HCM's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
INCR vs TRLV Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while TRLV trades at $11.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas TRLV's P/E ratio is -4.78. In terms of profitability, INCR's ROE is -0.09%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, INCR is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for INCR.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
INCR vs PRGO Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while PRGO trades at $14.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas PRGO's P/E ratio is 5.77. In terms of profitability, INCR's ROE is -0.09%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, INCR is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for INCR.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
INCR vs EMBCV Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas EMBCV's P/E ratio is N/A. In terms of profitability, INCR's ROE is -0.09%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, INCR is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for INCR.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
INCR vs DVAX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas DVAX's P/E ratio is -41.89. In terms of profitability, INCR's ROE is -0.09%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, INCR is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for INCR.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
INCR vs ALVO Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ALVO trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ALVO's P/E ratio is -15.41. In terms of profitability, INCR's ROE is -0.09%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, INCR is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for INCR.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
INCR vs ETON Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ETON has a market cap of 1.7B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ETON trades at $60.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ETON's P/E ratio is 131.37. In terms of profitability, INCR's ROE is -0.09%, compared to ETON's ROE of +0.40%. Regarding short-term risk, INCR is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
INCR vs ANIP Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ANIP trades at $71.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ANIP's P/E ratio is 8.75. In terms of profitability, INCR's ROE is -0.09%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, INCR is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
INCR vs TARO Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas TARO's P/E ratio is 30.05. In terms of profitability, INCR's ROE is -0.09%, compared to TARO's ROE of +0.03%. Regarding short-term risk, INCR is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for INCR.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
INCR vs PAHC Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while PAHC trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas PAHC's P/E ratio is 13.10. In terms of profitability, INCR's ROE is -0.09%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, INCR is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for INCR.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
INCR vs HROW Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while HROW trades at $36.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas HROW's P/E ratio is -37.34. In terms of profitability, INCR's ROE is -0.09%, compared to HROW's ROE of -1.04%. Regarding short-term risk, INCR is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for INCR.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
INCR vs CRON Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while CRON trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas CRON's P/E ratio is 32.10. In terms of profitability, INCR's ROE is -0.09%, compared to CRON's ROE of +0.06%. Regarding short-term risk, INCR is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for INCR.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
INCR vs PCRX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while PCRX trades at $26.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas PCRX's P/E ratio is 10.18. In terms of profitability, INCR's ROE is -0.09%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, INCR is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for INCR.Check PCRX's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
INCR vs AMPH Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, AMPH has a market cap of 1B. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while AMPH trades at $22.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas AMPH's P/E ratio is 7.84. In terms of profitability, INCR's ROE is -0.09%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, INCR is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for INCR.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
INCR vs PETQ Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas PETQ's P/E ratio is 83.73. In terms of profitability, INCR's ROE is -0.09%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, INCR is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for INCR.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
INCR vs COLL Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, COLL has a market cap of 778.4M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while COLL trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas COLL's P/E ratio is 3.01. In terms of profitability, INCR's ROE is -0.09%, compared to COLL's ROE of +0.16%. Regarding short-term risk, INCR is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for INCR.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
INCR vs IRWD Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, IRWD has a market cap of 702.9M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while IRWD trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas IRWD's P/E ratio is 5.47. In terms of profitability, INCR's ROE is -0.09%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, INCR is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for INCR.Check IRWD's competition here
Glass House Brands Inc (NYSE: GLAS)
INCR vs GLAS Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, GLAS has a market cap of 657.7M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while GLAS trades at $8.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas GLAS's P/E ratio is -15.18. In terms of profitability, INCR's ROE is -0.09%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, INCR is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for INCR.Check GLAS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
INCR vs AQST Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, AQST has a market cap of 657.4M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while AQST trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas AQST's P/E ratio is -8.06. In terms of profitability, INCR's ROE is -0.09%, compared to AQST's ROE of +2.44%. Regarding short-term risk, INCR is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for INCR.Check AQST's competition here
Evotec SE (NASDAQ: EVO)
INCR vs EVO Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, EVO has a market cap of 639.4M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while EVO trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas EVO's P/E ratio is -2.54. In terms of profitability, INCR's ROE is -0.09%, compared to EVO's ROE of -0.27%. Regarding short-term risk, INCR is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for INCR.Check EVO's competition here
Evolus, Inc. (NASDAQ: EOLS)
INCR vs EOLS Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, EOLS has a market cap of 598M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while EOLS trades at $9.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas EOLS's P/E ratio is -28.75. In terms of profitability, INCR's ROE is -0.09%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, INCR is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for INCR.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
INCR vs BDSI Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas BDSI's P/E ratio is 6.82. In terms of profitability, INCR's ROE is -0.09%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, INCR is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for INCR.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
INCR vs TLRY Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, TLRY has a market cap of 503.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while TLRY trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas TLRY's P/E ratio is -4.15. In terms of profitability, INCR's ROE is -0.09%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, INCR is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for INCR.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
INCR vs KMDA Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, KMDA has a market cap of 483.5M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while KMDA trades at $8.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas KMDA's P/E ratio is 22.05. In terms of profitability, INCR's ROE is -0.09%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, INCR is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for INCR.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
INCR vs CGC Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, CGC has a market cap of 411.6M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while CGC trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas CGC's P/E ratio is -0.59. In terms of profitability, INCR's ROE is -0.09%, compared to CGC's ROE of -0.33%. Regarding short-term risk, INCR is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for INCR.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
INCR vs TKNO Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, TKNO has a market cap of 379.6M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while TKNO trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas TKNO's P/E ratio is -22.84. In terms of profitability, INCR's ROE is -0.09%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, INCR is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for INCR.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
INCR vs EBS Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, EBS has a market cap of 320.9M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while EBS trades at $6.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas EBS's P/E ratio is 4.32. In terms of profitability, INCR's ROE is -0.09%, compared to EBS's ROE of -0.36%. Regarding short-term risk, INCR is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for INCR.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
INCR vs ALIM Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ALIM's P/E ratio is 5.28. In terms of profitability, INCR's ROE is -0.09%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, INCR is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
INCR vs LNDC Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas LNDC's P/E ratio is -4.04. In terms of profitability, INCR's ROE is -0.09%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, INCR is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for INCR.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
INCR vs ACB Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ACB has a market cap of 250.9M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ACB trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ACB's P/E ratio is -8.27. In terms of profitability, INCR's ROE is -0.09%, compared to ACB's ROE of -0.21%. Regarding short-term risk, INCR is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ACB's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
INCR vs CRDL Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, CRDL has a market cap of 247.8M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while CRDL trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas CRDL's P/E ratio is -8.57. In terms of profitability, INCR's ROE is -0.09%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, INCR is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for INCR.Check CRDL's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
INCR vs SIGA Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, SIGA has a market cap of 232.4M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while SIGA trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas SIGA's P/E ratio is 12.00. In terms of profitability, INCR's ROE is -0.09%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, INCR is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for INCR.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
INCR vs TYHT Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas TYHT's P/E ratio is -1.61. In terms of profitability, INCR's ROE is -0.09%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, INCR is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for INCR.Check TYHT's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
INCR vs ORGO Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ORGO has a market cap of 209.7M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ORGO trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ORGO's P/E ratio is 54.33. In terms of profitability, INCR's ROE is -0.09%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, INCR is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ORGO's competition here
Journey Medical Corporation (NASDAQ: DERM)
INCR vs DERM Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, DERM has a market cap of 208.3M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while DERM trades at $7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas DERM's P/E ratio is -20.46. In terms of profitability, INCR's ROE is -0.09%, compared to DERM's ROE of -0.20%. Regarding short-term risk, INCR is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for INCR.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
INCR vs REPH Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas REPH's P/E ratio is -8.04. In terms of profitability, INCR's ROE is -0.09%, compared to REPH's ROE of -0.22%. Regarding short-term risk, INCR is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for INCR.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
INCR vs OGI Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, OGI has a market cap of 166.1M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while OGI trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas OGI's P/E ratio is 2.65. In terms of profitability, INCR's ROE is -0.09%, compared to OGI's ROE of +0.21%. Regarding short-term risk, INCR is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for INCR.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
INCR vs LFCR Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, LFCR has a market cap of 164.7M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while LFCR trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas LFCR's P/E ratio is -4.10. In terms of profitability, INCR's ROE is -0.09%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, INCR is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for INCR.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
INCR vs THTX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas THTX's P/E ratio is -28.83. In terms of profitability, INCR's ROE is -0.09%, compared to THTX's ROE of +0.17%. Regarding short-term risk, INCR is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for INCR.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
INCR vs ASRT Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ASRT's P/E ratio is -7.10. In terms of profitability, INCR's ROE is -0.09%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, INCR is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
INCR vs SCTL Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas SCTL's P/E ratio is -7.86. In terms of profitability, INCR's ROE is -0.09%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, INCR is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for INCR.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
INCR vs BGM Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, BGM has a market cap of 103.9M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while BGM trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas BGM's P/E ratio is -0.94. In terms of profitability, INCR's ROE is -0.09%, compared to BGM's ROE of -0.05%. Regarding short-term risk, INCR is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for INCR.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
INCR vs PROC Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas PROC's P/E ratio is 1.53. In terms of profitability, INCR's ROE is -0.09%, compared to PROC's ROE of -2.22%. Regarding short-term risk, INCR is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for INCR.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
INCR vs CPIX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, CPIX has a market cap of 98.3M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while CPIX trades at $6.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas CPIX's P/E ratio is -16.40. In terms of profitability, INCR's ROE is -0.09%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, INCR is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for INCR.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
INCR vs OPTN Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas OPTN's P/E ratio is -4.42. In terms of profitability, INCR's ROE is -0.09%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, INCR is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for INCR.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
INCR vs ZOM Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ZOM's P/E ratio is -1.62. In terms of profitability, INCR's ROE is -0.09%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, INCR is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for INCR.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
INCR vs GRVI Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas GRVI's P/E ratio is 26.05. In terms of profitability, INCR's ROE is -0.09%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, INCR is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for INCR.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
INCR vs ZYBT Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ZYBT has a market cap of 78.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ZYBT trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ZYBT's P/E ratio is -7.50. In terms of profitability, INCR's ROE is -0.09%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, INCR is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for INCR.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
INCR vs ZYNE Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, INCR's ROE is -0.09%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, INCR is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for INCR.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
INCR vs SSIC Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas SSIC's P/E ratio is 11.93. In terms of profitability, INCR's ROE is -0.09%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, INCR is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for INCR.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
INCR vs VLNS Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas VLNS's P/E ratio is -1.03. In terms of profitability, INCR's ROE is -0.09%, compared to VLNS's ROE of N/A. Regarding short-term risk, INCR is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for INCR.Check VLNS's competition here
Talphera, Inc. (NASDAQ: TLPH)
INCR vs TLPH Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, TLPH has a market cap of 61.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while TLPH trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas TLPH's P/E ratio is -3.81. In terms of profitability, INCR's ROE is -0.09%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, INCR is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for INCR.Check TLPH's competition here
DURECT Corporation (NASDAQ: DRRX)
INCR vs DRRX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas DRRX's P/E ratio is -4.44. In terms of profitability, INCR's ROE is -0.09%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, INCR is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for INCR.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
INCR vs JUPW Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas JUPW's P/E ratio is -2.41. In terms of profitability, INCR's ROE is -0.09%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, INCR is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for INCR.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
INCR vs QLI Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas QLI's P/E ratio is -4.92. In terms of profitability, INCR's ROE is -0.09%, compared to QLI's ROE of -0.16%. Regarding short-term risk, INCR is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for INCR.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
INCR vs CPHI Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, CPHI has a market cap of 35.8M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while CPHI trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas CPHI's P/E ratio is -2.06. In terms of profitability, INCR's ROE is -0.09%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, INCR is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for INCR.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
INCR vs RMTI Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, RMTI has a market cap of 32.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while RMTI trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas RMTI's P/E ratio is -6.10. In terms of profitability, INCR's ROE is -0.09%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, INCR is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for INCR.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
INCR vs HEXO Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas HEXO's P/E ratio is -0.26. In terms of profitability, INCR's ROE is -0.09%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, INCR is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for INCR.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
INCR vs TXMD Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, TXMD has a market cap of 25.1M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while TXMD trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas TXMD's P/E ratio is 110.55. In terms of profitability, INCR's ROE is -0.09%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, INCR is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for INCR.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
INCR vs AYTU Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, AYTU has a market cap of 24.1M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while AYTU trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas AYTU's P/E ratio is -1.17. In terms of profitability, INCR's ROE is -0.09%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, INCR is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for INCR.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
INCR vs CYTH Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas CYTH's P/E ratio is -0.80. In terms of profitability, INCR's ROE is -0.09%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, INCR is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for INCR.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
INCR vs EVOK Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas EVOK's P/E ratio is -7.97. In terms of profitability, INCR's ROE is -0.09%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, INCR is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for INCR.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
INCR vs OPTH Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, OPTH has a market cap of 16.1M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while OPTH trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas OPTH's P/E ratio is -18.26. In terms of profitability, INCR's ROE is -0.09%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, INCR is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for INCR.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
INCR vs ACRX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ACRX's P/E ratio is -0.31. In terms of profitability, INCR's ROE is -0.09%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, INCR is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for INCR.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
INCR vs CABR Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, CABR has a market cap of 12.4M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while CABR trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas CABR's P/E ratio is -2.43. In terms of profitability, INCR's ROE is -0.09%, compared to CABR's ROE of -3.86%. Regarding short-term risk, INCR is more volatile compared to CABR. This indicates higher risk in terms of short-term price fluctuations for INCR.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
INCR vs AGRX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas AGRX's P/E ratio is -0.89. In terms of profitability, INCR's ROE is -0.09%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, INCR is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for INCR.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
INCR vs NLTX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas NLTX's P/E ratio is -0.28. In terms of profitability, INCR's ROE is -0.09%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, INCR is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for INCR.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
INCR vs LCI Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas LCI's P/E ratio is -0.04. In terms of profitability, INCR's ROE is -0.09%, compared to LCI's ROE of +1.66%. Regarding short-term risk, INCR is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for INCR.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
INCR vs ADMP Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ADMP's P/E ratio is -0.08. In terms of profitability, INCR's ROE is -0.09%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, INCR is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
INCR vs YCBD Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, YCBD has a market cap of 5.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while YCBD trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas YCBD's P/E ratio is -1.22. In terms of profitability, INCR's ROE is -0.09%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, INCR is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for INCR.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
INCR vs GELS Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while GELS trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas GELS's P/E ratio is -1.08. In terms of profitability, INCR's ROE is -0.09%, compared to GELS's ROE of -0.25%. Regarding short-term risk, INCR is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for INCR.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
INCR vs MNK Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas MNK's P/E ratio is -0.44. In terms of profitability, INCR's ROE is -0.09%, compared to MNK's ROE of -0.36%. Regarding short-term risk, INCR is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for INCR.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
INCR vs FLGC Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas FLGC's P/E ratio is -0.19. In terms of profitability, INCR's ROE is -0.09%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, INCR is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for INCR.Check FLGC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
INCR vs SBFM Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while SBFM trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas SBFM's P/E ratio is -0.19. In terms of profitability, INCR's ROE is -0.09%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, INCR is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for INCR.Check SBFM's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
INCR vs RDHL Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, RDHL has a market cap of 2.7M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while RDHL trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas RDHL's P/E ratio is 0.17. In terms of profitability, INCR's ROE is -0.09%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, INCR is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for INCR.Check RDHL's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
INCR vs UPC Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, UPC has a market cap of 2.7M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while UPC trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas UPC's P/E ratio is -0.53. In terms of profitability, INCR's ROE is -0.09%, compared to UPC's ROE of -0.03%. Regarding short-term risk, INCR is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for INCR.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
INCR vs PLXP Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas PLXP's P/E ratio is -0.22. In terms of profitability, INCR's ROE is -0.09%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, INCR is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for INCR.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
INCR vs ATNX Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas ATNX's P/E ratio is -0.02. In terms of profitability, INCR's ROE is -0.09%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, INCR is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for INCR.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
INCR vs SNOA Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while SNOA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas SNOA's P/E ratio is -1.09. In terms of profitability, INCR's ROE is -0.09%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, INCR is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for INCR.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
INCR vs SHPH Comparison September 2026
InterCure Ltd. (NASDAQ: INCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCR stands at 65.3M. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, INCR is priced at $5.51 on the NASDAQ, while SHPH trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCR currently has a P/E ratio of -12.72, whereas SHPH's P/E ratio is -0.17. In terms of profitability, INCR's ROE is -0.09%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, INCR is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for INCR.Check SHPH's competition here